Demo environment. All data shown is synthetic. VXSPR is intended for financial and operational ROI analytics only — not a medical device, diagnostic tool, or substitute for clinical judgment.
Executive Summary
Portfolio-wide therapeutic contract performance, FY 2024.
AI Executive Summary
This contract portfolio is currently generating a projected 38.2% ROI, driven primarily by reduced inpatient utilization (7,270 avoided hospitalizations) and improved therapy adherence (74.7% portfolio average). Net savings of $13.13M exceed contract cost across 4 of 12 active agreements. 8 contracts warrant intervention before renewal.
Total contract value
$34.41M
Estimated gross savings
$47.54M
Net savings
$13.13M
Portfolio ROI
38.2%
PMPM savings
$2.56
Per member, per month
Avoided hospitalizations
7,270
Avoided ER visits
15,034
Adherence improvement
74.7%
Portfolio average
Contract performance score
58 / 100